Traws Pharma Statistics
Total Valuation
Traws Pharma has a market cap or net worth of $7.98 million. The enterprise value is -$8.29 million.
Important Dates
The last earnings date was Thursday, May 15, 2025, before market open.
| Earnings Date | May 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Traws Pharma has 5.56 million shares outstanding. The number of shares has increased by 266.94% in one year.
| Current Share Class | 5.56M |
| Shares Outstanding | 5.56M |
| Shares Change (YoY) | +266.94% |
| Shares Change (QoQ) | +134.30% |
| Owned by Insiders (%) | 6.59% |
| Owned by Institutions (%) | 6.74% |
| Float | 3.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 19.29 |
| Forward PS | 41.67 |
| PB Ratio | 1.32 |
| P/TBV Ratio | 1.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.81
| Current Ratio | 1.81 |
| Quick Ratio | 1.69 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -2,331.25% and return on invested capital (ROIC) is -259.06%.
| Return on Equity (ROE) | -2,331.25% |
| Return on Assets (ROA) | -83.59% |
| Return on Invested Capital (ROIC) | -259.06% |
| Return on Capital Employed (ROCE) | -287.47% |
| Revenue Per Employee | $32,429 |
| Profits Per Employee | -$4.94M |
| Employee Count | 7 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.00% in the last 52 weeks. The beta is 1.59, so Traws Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.59 |
| 52-Week Price Change | -90.00% |
| 50-Day Moving Average | 1.72 |
| 200-Day Moving Average | 5.06 |
| Relative Strength Index (RSI) | 46.95 |
| Average Volume (20 Days) | 194,719 |
Short Selling Information
The latest short interest is 74,699, so 1.34% of the outstanding shares have been sold short.
| Short Interest | 74,699 |
| Short Previous Month | 73,982 |
| Short % of Shares Out | 1.34% |
| Short % of Float | 1.98% |
| Short Ratio (days to cover) | 0.61 |
Income Statement
In the last 12 months, Traws Pharma had revenue of $227,000 and -$34.61 million in losses. Loss per share was -$11.22.
| Revenue | 227,000 |
| Gross Profit | 227,000 |
| Operating Income | -24.90M |
| Pretax Income | -18.16M |
| Net Income | -34.61M |
| EBITDA | -24.89M |
| EBIT | -24.90M |
| Loss Per Share | -$11.22 |
Full Income StatementBalance Sheet
The company has $15.94 million in cash and n/a in debt, giving a net cash position of $15.94 million or $2.86 per share.
| Cash & Cash Equivalents | 15.94M |
| Total Debt | n/a |
| Net Cash | 15.94M |
| Net Cash Per Share | $2.86 |
| Equity (Book Value) | 6.00M |
| Book Value Per Share | 1.08 |
| Working Capital | 8.46M |
Full Balance SheetCash Flow
| Operating Cash Flow | -30.81M |
| Capital Expenditures | n/a |
| Free Cash Flow | -30.81M |
| FCF Per Share | -$5.54 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -10,969.60% |
| Pretax Margin | -61,696.04% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |